The Latest Breaking News from Novavax

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. Novavax was up 13% at $93.70 Monday afternoon at publication.

Novavax Inc (NASDAQ: NVAX) is trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373.

Novavax Inc. (NASDAQ: NVAX) shares lost ground Monday fell below support in a pennant pattern. The stock has also seen a strong drop in its Relative Strength Index. Novavax was down 6.12% at $79.47 at the close Monday.

Someone with a lot of money to spend has taken a bearish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Novavax COVID-19 vaccine has been approved in Australia, and it's set to play a big part in future vaccine rollouts around the world.

The vaccine now has the final approval from ATAGI and is set to be rolled out across the country toward the end of February.

This blog is now closed

Australia’s government is hoping the protein-based vaccine – approved by the TGA – will sway the hesitant to get the jab

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Thursday after Australia’s national drug regulator granted approval for the company's COVID-19 vaccine. The stock is trading below what traders call a pennant pattern and is showing uncertainty in where it could head next.